指数调整蓄势，恒生创新药ETF（159316）持续获资金抢筹，规模创历史新高

Core Insights - The Hong Kong pharmaceutical sector experienced a slight pullback, with the Hong Kong Stock Connect Innovative Drug Index declining approximately 0.8% [1] - Recent performance indicates a significant reduction in downward momentum since October 23 [1] - The Hang Seng Innovative Drug ETF (159316) has seen over 130 million yuan in trading volume as of 10:36 AM, with continuous net inflows for six months since May, doubling its fund size to a historical high of 3.65 billion yuan since early September [1] - Chinese innovative pharmaceutical companies set a record at the ESMO conference, with 35 studies selected for oral presentations and 23 for breakthrough abstracts, covering prevalent cancers such as liver cancer, lung cancer, and lymphoma [1] - Major collaborations are on the rise, exemplified by Innovent Biologics and Takeda's agreement involving an upfront payment of 1.2 billion USD, with a total scale reaching up to 11.4 billion USD, reflecting global pharmaceutical companies' recognition of Chinese innovative drugs [1] - Analysts suggest that recent signals of easing US-China relations, combined with the onset of the fourth quarter's business development peak for innovative drugs, may lead to a recovery in sector sentiment [1] - The Hang Seng Stock Connect Innovative Drug Index may have entered a phase of relative low valuation after adjustments, highlighting increasing investment value [1] Industry Overview - The Hang Seng Stock Connect Innovative Drug Index is one of the first "pure" 100% innovative drug indices, accurately reflecting the overall performance of China's innovative pharmaceutical companies [2] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, providing investors with opportunities to capitalize on industry development [2]